NMN vs NR: Which NAD+ Precursor is Better?

NMN

NMN (nicotinamide mononucleotide) is a direct precursor to NAD+, sitting one enzymatic step closer than NR. Once absorbed, NMN is converted to NAD+ via the NMNAT enzyme family. Research by David Sinclair's lab at Harvard demonstrated that NMN supplementation restored NAD+ levels and improved vascular function in aged mice. A 2022 human trial by Igarashi et al. showed that oral NMN (250 mg/day) increased blood NAD+ levels in healthy adults without adverse effects.

NR

NR (nicotinamide riboside) is converted to NMN via the nicotinamide riboside kinase (NRK) enzymes before being incorporated into NAD+. This extra step was historically thought to be rate-limiting, but research suggests NRK activity is not typically the bottleneck. Charles Brenner, who identified NR as a vitamin B3 precursor, has published extensively on its safety and NAD+-raising efficacy. NR appears to be well-absorbed in oral form and reliably raises whole-blood NAD+ levels.

NMN

Early dogma held that NMN could not cross the intestinal membrane intact and must first be converted to NR. A 2023 study in Nature Metabolism identified a dedicated NMN transporter (Slc12a8) in intestinal cells, suggesting NMN can be absorbed directly. More recent human pharmacokinetic data confirm that NMN raises blood NMN levels significantly within 2–3 hours of ingestion, though downstream tissue uptake kinetics are still being characterised. Sublingual and liposomal NMN formulations have been marketed to bypass gut degradation, though comparative data are limited.

NR

NR's bioavailability in oral form is well-documented. Multiple human pharmacokinetic studies demonstrate rapid conversion to NMN and NAD+ metabolites in blood within 1–4 hours. Notably, a significant fraction of orally ingested NR is converted to nicotinamide (NAM) in the gut before reaching systemic circulation, which itself contributes to NAD+ synthesis. This means the effective dose reaching target tissues may be lower than stated on the label, but the systemic NAD+-raising effect remains robust.

NMN

Human trials for NMN have accelerated since 2021. Notable studies include a 2022 trial in older adults showing improved muscle insulin sensitivity with 250 mg/day NMN, and a 2023 study demonstrating improved aerobic capacity in amateur runners. However, the total number of randomised controlled trials remains below 20, and most are small (n < 50). Long-term safety data beyond 12 months are scarce.

NR

NR has been studied in humans since 2016 and has accumulated the largest body of clinical evidence among NAD+ precursors. A 2018 study in Nature Communications (n=120) showed NR safely raised NAD+ by 40–50% at doses of 1000 mg/day. Subsequent trials have examined effects on cardiovascular risk, skeletal muscle function, and cognitive aging. While effect sizes on clinical outcomes are modest, the safety profile across trials is consistently reassuring.

NMN

NMN has become significantly cheaper as production has scaled. Quality NMN from reputable suppliers (e.g., Tru Niagen competitor products, DoNotAge, Renue By Science) now runs $40–80/month for 500 mg/day doses. However, purity and actual NMN content vary substantially across brands — third-party certificate of analysis (CoA) verification is essential. NMN is sold as a supplement in the US and most countries but faced a brief FDA enforcement ambiguity in 2022–2023.

NR

NR is sold under several brand names, with Tru Niagen (ChromaDex/Elysium Basis) being the most clinically studied branded form. Branded NR carries a price premium ($50–90/month for 300–500 mg/day) compared to generic NMN. Generic NR is available at lower prices but with less supporting manufacturing transparency. NR's regulatory status as a dietary supplement is more settled than NMN's in the US.

NMN

NMN is generally well-tolerated in trials to date. Reported adverse effects are minor — occasional flushing (less than with nicotinic acid), mild GI upset, and fatigue at very high doses. No serious adverse events have been reported in clinical trials. Long-term effects (>1 year) are unknown, and there is theoretical concern about NMN supplementation in individuals with cancer due to NAD+'s role in fuelling rapidly dividing cells, though no human data confirm this risk.

NR

NR's safety profile is the most comprehensively studied among NAD+ precursors. Multiple trials including doses up to 2000 mg/day have found no significant adverse effects. NR does not cause the flushing associated with nicotinic acid. Like NMN, the theoretical oncology concern exists. One distinguishing safety note: NR metabolism produces methylated nicotinamide, raising questions about chronic methyl group demand — relevant for individuals with MTHFR variants or low dietary methyl donors.